# Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

## Metadata
**Authors:** Adam M Lee, Qian Shi, Steven R Alberts, Daniel J Sargent, Frank A Sinicrope, Jeffrey L Berenberg, Axel Grothey, Blase Polite, Emily Chan, Sharlene Gill, Morton S Kahlenberg, Suresh G Nair, Anthony F Shields, Richard M Goldberg, Robert B Diasio
**Journal:** Pharmacogenetics and genomics
**Date:** 2016 Mar
**DOI:** [10.1097/FPC.0000000000000197](https://doi.org/10.1097/FPC.0000000000000197)
**PMID:** 26658227
**PMCID:** PMC4738010
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738010/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC4738010/pdf/nihms739479.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC4738010/pdf/nihms739479.pdf)

## Abstract

Severe (grade≥3) adverse events (AEs) to 5-fluorouracil (5-FU)-based chemotherapy regimens can result in treatment delays or cessation, and, in extreme cases, life-threatening complications. Current genetic biomarkers for 5-FU toxicity prediction, however, account for only a small proportion of toxic cases. In the current study, we assessed DPYD variants suggested to correlate with 5-FU toxicity, a deep intronic variant (c.1129-5923 C>G) and four variants within a haplotype (hapB3), in 1953 stage III colon cancer patients who received adjuvant FOLFOX +/- cetuximab. Logistic regression was used to assess multivariable associations between DPYD variant status and AEs common to 5-FU (5FU-AEs). In our study cohort, 1228 patients (62.9%) reported any grade≥3 AE (overall AE), with 638 patients (32.7%) reporting any grade≥3 5FU-AE. Only 32 of 78 (41.0%) patients carrying DPYD c.1129-5923 C>G and the completely linked hapB3 variants c.1236 C>G and c.959-51 T>C displayed at least one grade≥3 5FU-AE, resulting in no statistically significant association (ORadj.=1.47, 95%CI=0.90-2.43, p=0.1267). No significant associations were identified between c.1129-5923 C>G/hapB3 and overall grade≥3 AE rate. Our results suggest that c.1129-5923 C>G/hapB3 have limited predictive value for severe toxicity to 5-FU-based combination chemotherapy.

Keywords: dihydropyrimidine dehydrogenase, polymorphism, pharmacogenetics, 5-fluorouracil, colon cancer, toxicity

## Supplementary Material

## Acknowledgments

The study funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The authors would also like to thank Dr. Steven M. Offer and Dr. Susan L. Slager (Mayo Clinic) for their statistical review of the genetic analyses aspects of the manuscript.

**Funding:** The study was supported by a National Cancer Institute Senior Scientist Award (K05CA142885 to F.A.S), the North Central Cancer Treatment Group (NCCTG) Biospecimen Resource National Institutes of Health grant (U24CA114740), and NIH grants R01CA062164 (R.B.D) and R01CA116964 (R.B.D). The study was also supported, in part, by the following grants from the National Cancer Institute: U10CA31946 to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, M.D., Chair), and U10CA33601 to the Alliance Statistics and Data Center (D. J. S). Support for correlative studies was also provided by unrestricted funds from Bristol-Myers Squibb, ImClone, Sanofi-Aventis, and Pfizer. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

## Footnotes

## Associated Data

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

### Supplementary Materials

### Supplementary Materials

## References

1. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98(3):610–615. doi: 10.1172/JCI118830.  [DOI](https://doi.org/10.1172/JCI118830) | [PMC free article](/articles/PMC507468/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8698850/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Invest&title=Molecular%20basis%20of%20the%20human%20dihydropyrimidine%20dehydrogenase%20deficiency%20and%205-fluorouracil%20toxicity&author=X%20Wei&author=HL%20McLeod&author=J%20McMurrough&author=FJ%20Gonzalez&author=P%20Fernandez-Salguero&volume=98&issue=3&publication_year=1996&pages=610-615&pmid=8698850&doi=10.1172/JCI118830&)

2. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705–4712.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/11156223/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Clinical%20implications%20of%20dihydropyrimidine%20dehydrogenase%20(DPD)%20deficiency%20in%20patients%20with%20severe%205-fluorouracil-associated%20toxicity:%20identification%20of%20new%20mutations%20in%20the%20DPD%20gene&author=AB%20van%20Kuilenburg&author=J%20Haasjes&author=DJ%20Richel&author=L%20Zoetekouw&author=H%20Van%20Lenthe&volume=6&issue=12&publication_year=2000&pages=4705-4712&pmid=11156223&)

3. Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11(16):5866–5892. doi: 10.1158/1078-0432.CCR-04-1784.  [DOI](https://doi.org/10.1158/1078-0432.CCR-04-1784) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16115930/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Analysis%20of%20the%20DPYD%20gene%20implicated%20in%205-fluorouracil%20catabolism%20in%20a%20cohort%20of%20Caucasian%20individuals&author=K%20Seck&author=S%20Riemer&author=R%20Kates&author=T%20Ullrich&author=V%20Lutz&volume=11&issue=16&publication_year=2005&pages=5866-5892&pmid=16115930&doi=10.1158/1078-0432.CCR-04-1784&)

4. Offer SM, Fossum CC, Wegner NJ, Stufflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74(9):2545–54. doi: 10.1158/0008-5472.CAN-13-2482.  [DOI](https://doi.org/10.1158/0008-5472.CAN-13-2482) | [PMC free article](/articles/PMC4012613/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24648345/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&title=Comparative%20functional%20analysis%20of%20DPYD%20variants%20of%20potential%20clinical%20relevance%20to%20dihydropyrimidine%20dehydrogenase%20activity&author=SM%20Offer&author=CC%20Fossum&author=NJ%20Wegner&author=AJ%20Stufflesser&author=GL%20Butterfield&volume=74&issue=9&publication_year=2014&pages=2545-54&pmid=24648345&doi=10.1158/0008-5472.CAN-13-2482&)

5. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895–2904. doi: 10.1158/1535-7163.MCT-06-0327.  [DOI](https://doi.org/10.1158/1535-7163.MCT-06-0327) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17121937/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Ther&title=Clinical%20relevance%20of%20different%20dihydropyrimidine%20dehydrogenase%20gene%20single%20nucleotide%20polymorphisms%20on%205-fluorouracil%20tolerance&author=A%20Morel&author=M%20Boisdron-Celle&author=L%20Fey&author=P%20Soulie&author=MC%20Craipeau&volume=5&issue=11&publication_year=2006&pages=2895-2904&pmid=17121937&doi=10.1158/1535-7163.MCT-06-0327&)

6. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131–2138. doi: 10.1200/JCO.2006.10.4182.  [DOI](https://doi.org/10.1200/JCO.2006.10.4182) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18299612/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Role%20of%20genetic%20and%20nongenetic%20factors%20for%20fluorouracil%20treatment-related%20severe%20toxicity:%20a%20prospective%20clinical%20trial%20by%20the%20German%205-FU%20Toxicity%20Study%20Group&author=M%20Schwab&author=UM%20Zanger&author=C%20Marx&author=E%20Schaeffeler&author=K%20Klein&volume=26&issue=13&publication_year=2008&pages=2131-2138&pmid=18299612&doi=10.1200/JCO.2006.10.4182&)

7. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing. Clin Pharmacol Ther. 2013;94(6):640–645. doi: 10.1038/clpt.2013.172.  [DOI](https://doi.org/10.1038/clpt.2013.172) | [PMC free article](/articles/PMC3831181/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23988873/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Clinical%20Pharmacogenetics%20Implementation%20Consortium%20Guidelines%20for%20Dihydropyrimidine%20Dehydrogenase%20Genotype%20and%20Fluoropyrimidine%20Dosing&author=KE%20Caudle&author=CF%20Thorn&author=TE%20Klein&author=JJ%20Swen&author=HL%20McLeod&volume=94&issue=6&publication_year=2013&pages=640-645&pmid=23988873&doi=10.1038/clpt.2013.172&)

8. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other 5-fluorouracil-based regimens: investigation in the QUASAR2 study, systemic review and meta-analysis. J Clin Oncol. 2014;32(10):1031–1039. doi: 10.1200/JCO.2013.51.1857.  [DOI](https://doi.org/10.1200/JCO.2013.51.1857) | [PMC free article](/articles/PMC4879695/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24590654/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Genetic%20markers%20of%20toxicity%20from%20capecitabine%20and%20other%205-fluorouracil-based%20regimens:%20investigation%20in%20the%20QUASAR2%20study,%20systemic%20review%20and%20meta-analysis&author=D%20Rosmarin&author=C%20Palles&author=D%20Church&author=E%20Domingo&author=A%20Jones&volume=32&issue=10&publication_year=2014&pages=1031-1039&pmid=24590654&doi=10.1200/JCO.2013.51.1857&)

9. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14(11):1255–1272. doi: 10.2217/pgs.13.116.  [DOI](https://doi.org/10.2217/pgs.13.116) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23930673/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics&title=DPYD%20IVS14+1G>A%20and%202846A>T%20genotyping%20for%20the%20prediction%20of%20severe%20fluoropyrimidine-related%20toxicity:%20a%20meta-analysis&author=S%20Terrazzino&author=S%20Cargnin&author=M%20Del%20Re&author=R%20Danesi&author=PL%20Canonico&volume=14&issue=11&publication_year=2013&pages=1255-1272&pmid=23930673&doi=10.2217/pgs.13.116&)

10. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147) J Natl Cancer Inst. 2014;106(12) doi: 10.1093/jnci/dju298. Print 2014 Dec.  [DOI](https://doi.org/10.1093/jnci/dju298) | [PMC free article](/articles/PMC4271081/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/25381393/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&title=DPYD%20variants%20as%20predictors%20of%205-fluorouracil%20toxicity%20in%20adjuvant%20colon%20cancer%20treatment%20(NCCTG%20N0147)&author=AM%20Lee&author=Q%20Shi&author=E%20Pavey&author=SR%20Alberts&author=DJ%20Sargent&volume=106&issue=12&publication_year=2014&pmid=25381393&doi=10.1093/jnci/dju298&)

11. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10(6):931–44. doi: 10.2217/pgs.09.28.  [DOI](https://doi.org/10.2217/pgs.09.28) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19530960/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics&title=Dihydropyrimidine%20dehydrogenase%20gene%20variation%20and%20severe%205-fluorouracil%20toxicity:%20a%20haplotype%20assessment&author=U%20Amstutz&author=S%20Farese&author=S%20Aebi&author=CR%20Largiader&volume=10&issue=6&publication_year=2009&pages=931-44&pmid=19530960&doi=10.2217/pgs.09.28&)

12. Van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, et al. Intrageneic deletions and a deep intronic mutation affecting pre-mRNA slicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet. 2010;128(5):529–38. doi: 10.1007/s00439-010-0879-3.  [DOI](https://doi.org/10.1007/s00439-010-0879-3) | [PMC free article](/articles/PMC2955237/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20803296/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hum%20Genet&title=Intrageneic%20deletions%20and%20a%20deep%20intronic%20mutation%20affecting%20pre-mRNA%20slicing%20in%20the%20dihydropyrimidine%20dehydrogenase%20gene%20as%20novel%20mechanisms%20causing%205-fluorouracil%20toxicity&author=AB%20Van%20Kuilenburg&author=J%20Meijer&author=AN%20Mul&author=R%20Meinsma&author=V%20Schmid&volume=128&issue=5&publication_year=2010&pages=529-38&pmid=20803296&doi=10.1007/s00439-010-0879-3&)

13. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17:3455–68. doi: 10.1158/1078-0432.CCR-10-2209.  [DOI](https://doi.org/10.1158/1078-0432.CCR-10-2209) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21498394/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Relationship%20between%20single%20nucleotide%20polymorphisms%20and%20haplotypes%20in%20DPYD%20and%20toxicity%20and%20efficacy%20of%20capecitabine%20in%20advanced%20colorectal%20cancer&author=MJ%20Deenen&author=J%20Tol&author=AM%20Burylo&author=VD%20Doodeman&author=A%20de%20Boer&volume=17&publication_year=2011&pages=3455-68&pmid=21498394&doi=10.1158/1078-0432.CCR-10-2209&)

14. Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadèr CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early onset fluoropyrimidine toxicity. Int J Cancer. 2015 Feb 15;136(3):730–9. doi: 10.1002/ijc.29025.  [DOI](https://doi.org/10.1002/ijc.29025) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24923815/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&title=Clinical%20importance%20of%20risk%20variants%20in%20the%20dihydropyrimidine%20dehydrogenase%20gene%20for%20the%20prediction%20of%20early%20onset%20fluoropyrimidine%20toxicity&author=TK%20Froehlich&author=U%20Amstutz&author=S%20Aebi&author=M%20Joerger&author=CR%20Largiad%C3%A8r&volume=136&issue=3&publication_year=2015&pages=730-9&pmid=24923815&doi=10.1002/ijc.29025&)

15. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One. 2008;3(12):e4003. doi: 10.1371/journal.pone.0004003.  [DOI](https://doi.org/10.1371/journal.pone.0004003) | [PMC free article](/articles/PMC2602733/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19104657/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=Strong%20association%20of%20a%20common%20dihydropyrimidine%20dehydrogenase%20gene%20polymorphism%20with%20fluoropyrimidine-related%20toxicity%20in%20cancer%20patients&author=E%20Gross&author=B%20Busse&author=M%20Riemenschneider&author=S%20Neubauer&author=K%20Seck&volume=3&issue=12&publication_year=2008&pages=e4003&pmid=19104657&doi=10.1371/journal.pone.0004003&)

16. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013 Jun 25;108(12):2505–15. doi: 10.1038/bjc.2013.262.  [DOI](https://doi.org/10.1038/bjc.2013.262) | [PMC free article](/articles/PMC3694243/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23736036/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Cancer&title=Pharmacogenetic%20variants%20in%20the%20DPYD,%20TYMS,%20CDA%20and%20MTHFR%20genes%20are%20clinically%20significant%20predictors%20of%20fluoropyrimidine%20toxicity&author=A%20Loganayagam&author=M%20Arenas%20Hernandez&author=A%20Corrigan&author=L%20Fairbanks&author=CM%20Lewis&volume=108&issue=12&publication_year=2013&pages=2505-15&pmid=23736036&doi=10.1038/bjc.2013.262&)

17. Jennings BA, Loke YK, Skinner J, Keane M, Chu GS, Turner R, et al. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One. 2013;8(10):e78053. doi: 10.1371/journal.pone.0078053.  [DOI](https://doi.org/10.1371/journal.pone.0078053) | [PMC free article](/articles/PMC3805522/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24167597/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=Evaluating%20predictive%20pharmacogenetic%20signatures%20of%20adverse%20events%20in%20colorectal%20cancer%20patients%20treated%20with%20fluoropyrimidines&author=BA%20Jennings&author=YK%20Loke&author=J%20Skinner&author=M%20Keane&author=GS%20Chu&volume=8&issue=10&publication_year=2013&pages=e78053&pmid=24167597&doi=10.1371/journal.pone.0078053&)

18. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383–1393. doi: 10.1001/jama.2012.385.  [DOI](https://doi.org/10.1001/jama.2012.385) | [PMC free article](/articles/PMC3442260/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22474202/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Effect%20of%20oxaliplatin,%20fluorouracil,%20and%20leucovorin%20with%20or%20without%20cetuximab%20on%20survival%20among%20patients%20with%20resected%20stage%20III%20colon%20cancer:%20a%20randomized%20trial&author=SR%20Alberts&author=DJ%20Sargent&author=S%20Nair&author=MR%20Mahoney&author=M%20Mooney&volume=307&publication_year=2012&pages=1383-1393&pmid=22474202&doi=10.1001/jama.2012.385&)

19. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56–65. doi: 10.1038/nature11632.  [DOI](https://doi.org/10.1038/nature11632) | [PMC free article](/articles/PMC3498066/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23128226/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature&title=An%20integrated%20map%20of%20genetic%20variation%20from%201,092%20human%20genomes&volume=491&publication_year=2012&pages=56-65&pmid=23128226&doi=10.1038/nature11632&)

20. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5. doi: 10.1093/bioinformatics/bth457.  [DOI](https://doi.org/10.1093/bioinformatics/bth457) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15297300/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Bioinformatics&title=Haploview:%20analysis%20and%20visualization%20of%20LD%20and%20haplotype%20maps&author=JC%20Barrett&author=B%20Fry&author=J%20Maller&author=MJ%20Daly&volume=21&publication_year=2005&pages=263-5&pmid=15297300&doi=10.1093/bioinformatics/bth457&)

21. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991.  [Google Scholar](https://scholar.google.com/scholar_lookup?title=Practical%20Statistics%20for%20Medical%20Research&author=DG%20Altman&publication_year=1991&)

22. Rosner B. Fundamentals of biostatistics. 5th. Pacific Grove, CA: Duxbury; 2000.  [Google Scholar](https://scholar.google.com/scholar_lookup?title=Fundamentals%20of%20biostatistics&author=B%20Rosner&publication_year=2000&)

23. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants as predictors of severe fluoropyrimidine-associated toxicity: a meta-analysis of individual patient data on DPYD variants c.1679 T>G, c.1236 G>A/HapB3, and c.1601 G>A. Lancet Oncol. 2015 doi: 10.1016/S1470-2045(15)00286-7. In Press.  [DOI](https://doi.org/10.1016/S1470-2045(15)00286-7) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/26603945/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&title=Clinical%20relevance%20of%20DPYD%20variants%20as%20predictors%20of%20severe%20fluoropyrimidine-associated%20toxicity:%20a%20meta-analysis%20of%20individual%20patient%20data%20on%20DPYD%20variants%20c.1679%20T>G,%20c.1236%20G>A/HapB3,%20and%20c.1601%20G>A&author=D%20Meulendijks&author=LM%20Henricks&author=GS%20Sonke&author=MJ%20Deenen&author=TK%20Froehlich&publication_year=2015&pmid=26603945&doi=10.1016/S1470-2045(15)00286-7&)

24. Database of Single Nucleotide Polymorphisms (dbSNP) Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine; (dbSNP Build ID: human 138). Available from: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?showRare=on&chooseRs=coding&go=Go&locusId=1806.  [http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?showRare=on&chooseRs=coding&go=Go&locusId=1806](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?showRare=on&chooseRs=coding&go=Go&locusId=1806) | [Google Scholar](https://scholar.google.com/scholar_lookup?title=Database%20of%20Single%20Nucleotide%20Polymorphisms%20(dbSNP)&)

25. Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther. 2014;13:742–51. doi: 10.1158/1535-7163.MCT-13-0878.  [DOI](https://doi.org/10.1158/1535-7163.MCT-13-0878) | [PMC free article](/articles/PMC3954441/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24401318/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Ther&title=microRNAs%20miR-27a%20and%20miR-27b%20directly%20regulate%20liver%20dihydropyrimidine%20dehydrogenase%20expression%20through%20two%20conserved%20binding%20sites&author=SM%20Offer&author=GL%20Butterfield&author=CR%20Jerde&author=CC%20Fossum&author=NJ%20Wegner&volume=13&publication_year=2014&pages=742-51&pmid=24401318&doi=10.1158/1535-7163.MCT-13-0878&)

26. Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR. Polymorphisms in MIR27A associated with early-onset toxicity in fluoropyrimidine-based chemotherapy. Clin Cancer Res. 2015;21:2038–44. doi: 10.1158/1078-0432.CCR-14-2817.  [DOI](https://doi.org/10.1158/1078-0432.CCR-14-2817) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/25655103/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Polymorphisms%20in%20MIR27A%20associated%20with%20early-onset%20toxicity%20in%20fluoropyrimidine-based%20chemotherapy&author=U%20Amstutz&author=SM%20Offer&author=J%20Sistonen&author=M%20Joerger&author=RB%20Diasio&volume=21&publication_year=2015&pages=2038-44&pmid=25655103&doi=10.1158/1078-0432.CCR-14-2817&)
